ArticleMetabolic brain disease2025
Amino acid patterns predict white matter integrity measures in the brain in patients across the Alzheimer's disease continuum.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum amino acid levels are associated with brain hypometabolism in patients across the Alzheimer's disease continuum.IBRO neuroscience reports · 2026Article
- Serum metabolomic profiling following cerebellar repetitive transcranial magnetic stimulation combined with cognitive training on Alzheimer's disease.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Alzheimer's disease (AD), the leading cause of dementia, poses a growing global health challenge due to its rising prevalence and socioeconomic impact. Investigating metabolic alterations associated with white matter integrity (WMI) could provide critical insights into AD pathogenesis and identify potential therapeutic targets. This cross-sectional study explored the associations between amino acid (AA) profiles, assessed via ultra-high-performance liquid chromatography (UHPLC), and WMI metrics derived from diffusion tensor imaging (DTI) in individuals across the AD continuum. A total of 176 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were included and grouped into cognitively normal (CN) individuals (n = 54), patients with mild cognitive impairment (MCI, n = 88), and AD patients (n = 34). WMI was evaluated using DTI-derived metrics, including fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD). AA profiling was conducted using an appropriate panel. Regression analyses, adjusted for age, gender, and education, was used to identify significant associations between AA levels and WMI. Distinct AA alterations were associated with white matter microstructural integrity across study groups. In CN individuals, higher levels of arginine, glycine, and threonine correlated with decreased FA and increased MD, indicating reduced white matter integrity. Conversely, in AD patients, aspartate, glutamate, and histidine exhibited opposite associations, showing positive correlations with FA and negative correlations with MD, suggesting potential neuroprotective or compensatory mechanisms. These findings underscore the associations between AA patterns and white matter integrity and their potential role as AD progression markers. Further investigations into these AA metabolism pathways may identify novel biomarkers for early diagnosis and targets for therapeutic interventions.
Indexed as
Identifiers
40531346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.